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CHAPTER 1 – INTRODUCTION 
Parkinson’s disease (PD) is a progressive neurodegenerative movement disorder 
characterized by specific loss of dopaminergic neurons in the substantia nigra pars 
compacta region of the midbrain. In the year 1817, James Parkinson originally described 
this disorder in a systematic manner as ‘shaking palsy’ (1). He described the symptoms 
of the disease in his early paper titled, “An Essay on the Shaking Palsy,” as “involuntary 
tremulous motion with lessened muscular power, in parts not in action and even when 
supported; with a propensity to bend the trunk forwards, and to pass from a walking to a 
running pace: the senses and intellects being uninjured” (1). Until 1877, the condition 
continued to be referred to as ‘paralysis agitans,’ when French neurologist Jean Charcot 
coined the term “Parkinson’s Disease” (2). However, it was not until 80 years later that 
the characteristics that eventually defined the disease came to the forefront during 
anatomical investigations that showed brain lesions in the post-mortem mid-brains of PD 
patients (2). Over the years, unraveling the underlying cellular mechanisms that 
particularly render the dopaminergic neurons vulnerable has been a subject of intense 
research. 
Following Alzheimer's disease, PD is the second most common neurological 
disease in both the USA and other industrialized nations, affecting over 1 million people 
in the USA itself (3). Apart from the specific degeneration of dopamine neurons, formation 
of protein aggregates called Lewy bodies is another major pathohistological hallmark 
commonly associated with the disorder (4). Lewy bodies are cytoplasmic inclusion bodies 
primarily containing intraneuronal protein deposits such as α-synuclein, ubiquitin, 
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neurofilaments and tau protein (5). Recent articles have suggested that such protein 
aggregates are not restricted to the substantia nigra or midbrain (6).  
Loss of dopamine (DA) neurons primarily affects the motor functions leading to 
symptoms such as bradykinesia, resting tremor, rigidity and postural instability among 
others (3). Accompanying motor deficits are also non-motor issues such as sleep 
disturbances, depression, anxiety and cognitive impairments (7,8). 
Epidemiological studies have revealed that most PD cases (90%) are sporadic and 
have a late onset with the median age of onset being around 65 years (9). Such cases 
that do not have a known genetic basis are also termed as idiopathic forms of PD. The 
remaining ~10% of cases are characterized by early onset and are typically associated 
with familial forms of PD (10). Development of Parkinsonian syndrome in such individuals 
has been attributed to mutations in several identified genes. Some of the genes known to 
be involved in such familial forms are α-synuclein (SNCA), ubiquitin C-terminal hydrolase 
(UCH-L1), parkin (PRKN), leucine rich repeat kinase-2 (LRRK-2), phosphatase and 
tensin homologue induced putative kinase 1 (PINK1), C57 peptidase (PARK7 or DJ-1), 
and probable cation-transporting ATPase 13A2 (ATP13A2) (11,12). Recent evidence 
however has suggested genetic predisposition as a risk factor for non-familial forms of 
PD (13).  
Parkinson’s disease represents a final outcome that involves complex interactions 
between multiple factors which surround the innate vulnerability of dopaminergic neurons 
in the nigro-striatal pathway. There are a number of factors known to contribute to 
neurodegeneration, such as dopamine oxidation (14,15), oxidative stress (16-18), 
mitochondrial dysfunction (19-21), genetic defects (11,12) and microglial inflammation 
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(22,23). Although multiple players have been implicated in the progression of the disease, 
the specific mechanisms connecting these disparate aspects have been elusive. 
Environmental factors such as pesticides and toxins directly induce both oxidative 
damage and mitochondrial dysfunction (24,25). Occupational uses of herbicides, 
exposure to organic solvents, carbon monoxide, and carbon disulfide, and more 
generally, industrialization, agricultural environment, well water, plant-derived toxins and 
bacterial and viral infection are all suggested to play roles (26-30). A number of cellular 
toxins are known to induce high-affinity specific inhibition of mitochondrial complex I or 
proteasomal inhibition, viz., rotenone, paraquat, epoxomicin, 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP). These toxicants have been popular study models for 
Parkinson’s disease due to their ability to mimic the specific loss of dopamine neurons 
(31-33). MPTP is known to cross the blood brain barrier easily after its systemic 
administration and gets converted to an actively toxic metabolite 1-methyl-4-phenyl-2,3-
dihydroxypyridinium ion (MPP+) by the enzyme monoamine oxidase-B (MAO-B). The 
metabolite MPP+ is selectively taken up into dopaminergic neurons by the dopamine 
transporter (DAT), where it is thought to irreversibly inhibit complex I of the mitochondrial 
respiratory chain, thereby producing selective degeneration of nigral dopamine cells (34-
36). Rotenone, on the other hand, is a well-known universal inhibitor of the mitochondrial 
respiratory chain. It inhibits the transfer of electrons from complex I to ubiquinone (37). 
What makes the rotenone model particularly interesting is, although it also leads to the 
formation of Lewy bodies, it is still not known how rotenone specifically targets 
dopaminergic neurons.  
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Mitochondrial dysfunction has long been implicated in the etiology and 
pathogenesis of Parkinson’s disease. Apart from defective respiration, perturbations in 
mitochondrial dynamics such as alterations in mitochondrial morphology and intracellular 
trafficking, are also involved. Chronic depletion of antioxidant defenses such as 
glutathione due to mitochondrial complex I impairment is suggestive of the interplay 
between oxidative stress and mitochondrial dysfunction. Mitochondrial damage may 
result from oxidative stress and, vice versa, its impairment may also enhance ROS/RNS 
release into the cytosol (38,39).  
Oxidative stress is also one of the major pathological factors involved in 
Parkinson’s disease. It is defined as a condition where the formation and accumulation of 
reactive oxygen and/or nitrogen species are favored over their removal, due to the 
defense mechanisms being overwhelmed. Factors such as proteasome pathology, 
microglial activation, neuro-inflammation and mitochondrial dysfunction, also identified as 
potential candidates in PD, have been closely associated to oxidative stress. Analysis of 
postmortem brains from PD patients revealed enhanced oxidative stress in the 
nigrostriatal dopaminergic neurons with a decreased ratio of GSH/GSSG (40), 
augmented levels of iron (41), increased lipid peroxidation (42), elevated keto-protein 
formation (43) and DNA oxidation (44). A relation has been shown in various animal 
models and in brains taken from deceased PD patients between neuronal destruction in 
the brain and the generation of massive oxidative stress. Betarbet et al. developed an in 
vivo rotenone-treated rat model for Parkinson’s disease (45). The rotenone-treated rats 
exhibited chronic inhibition of complex I of the mitochondrial electron transport chain in 
the brain. Moreover, the model exhibited highly specific neurodegeneration of nigrostriatal 
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dopaminergic neurons along with the symptoms characteristic of PD – Lewy body 
formation, motor deficits, hypokinesia and rigidity.  
Of late, the role of oxidative stress in Parkinson’s disease has been highly 
controversial. A major contention has been that the appearance of the oxidative 
biochemical markers may be due to some other causative factor involved in neuro-
degeneration, rather than the reverse (46,47). Thus the question whether oxidative stress 
is involved as the cause or consequence of the neurodegeneration of PD is still wide 
open. Also, the fact that many non-dopaminergic pathways are affected in the process 
has brought into question the significance of dopamine oxidation as the causative agent 
of oxidative stress. Therefore, it is imperative to differentiate between the cause and the 
consequence, to elucidate the mechanism underlying dopaminergic cell death in order to 
understand the etiology of Parkinson’s Disease. 
Dopaminergic neurons comprise 1% of the total brain neurons, but they control 
numerous functions in the brain. Some of the critical functions where dopaminergic 
neurons play a role are movement, motivation and reward, learning, emotion, cognition 
and pain pathways (48). They originate in the ventral tegmental area, in the substantia 
nigra and in the hypothalamus. These dopamine neurons project their axons to other 
areas of the brain building a complex neuronal network encompassing four major 
pathways. First, the mesolimbic pathway that connects the ventral tegmental area to the 
limbic system, controls memory and motivating behaviors. Second, the mesocortical 
pathway projects to the frontal cortex and surrounding structures. Third, the 
tuberoinfundibular pathway secretes hormones such as prolactin by connecting the 
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hypothalamus to the pituitary gland. And fourth, the nigrostriatal pathway, in which axons 
project from the substantia nigra to the striatum, controls the motor functions. 
The synthesis of dopamine takes place in the cytoplasmic compartment by the 
action of tyrosine hydroxylase (TH) on the amino acid tyrosine. In this hydroxylation step, 
tyrosine hydroxylase is a monoxygenase enzyme that uses tyrosine and molecular 
oxygen as substrates and tetrahydrobiopterin and iron as co-factors. This is the rate 
limiting step in the biosynthetic pathway of dopamine. The resulting product, L-3,4-
dihydroxyphenylalanine (L-DOPA), is then decarboxylated by aromatic amino acid 
decarboxylase (AADC) to dopamine. Once dopamine is formed, it is rapidly sequestered 
into synaptic vesicles by the action of vesicular monoamine transporter 2 (VMAT2), where 
low pH prevents its auto-oxidation. When dopamine is released in to the synaptic cleft, 
the dopamine transporter (DAT) ensures rapid DA reuptake (49). If free dopamine levels 
in the cytosol or synaptic cleft exceed transport capacity, it can be metabolized via 
enzymatic or non-enzymatic oxidative pathways.  
Studies with animal models, neuronal cell lines and also various post mortem brain 
studies have hinted at the potential role of dopamine and/or its metabolites as 
endogenous neurotoxic agents, influencing redox balance, ROS production and oxidative 
stress (14,15,50,51). This may be due to redox cycling of catechols, leading to increased 
generation of detrimental ROS. The catechol ring (ortho-dihydroxybenzene) of dopamine 
contributes significant toxicity to its structure. Hasegawa et al. showed that oxidized 
catechol metabolites cause apoptotic death of dopaminergic neurons and this process 
was exacerbated by alpha-synuclein, a major constituent of Lewy bodies (15). Moreover, 
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these metabolites could form adducts with alpha-synuclein leading to α-synuclein 
oligomerization, disruption of mitochondrial membrane potential and cell death (52). 
The oxidation of dopamine gives rise to quinone formation, both semi-quinone as 
well as ortho-quinone. DA oxidation can result in the formation of radicals (semi-quinones) 
and quinones via one- and two-electron oxidations, respectively (53-57). This process is 
enhanced in the presence of metal ions such as iron, copper, or manganese by Fenton 
chemistry leading to increased production of reactive oxygen/nitrogen species. Research 
has shown that dopamine cytotoxicity is primarily due to the formation of dopamine 
quinone (54,58), which is more powerful and toxic than quinones produced from other 
catecholamines. Also, intrastriatal injection of dopamine to normal rats in a dose-
dependent manner results in formation of lesions in the corpus striatum that was found to 
be mediated by quinone formation (58,59). The dopamine quinone also reacts with the 
sulfhydryl group of cysteine possibly leading to protein modification (55,60,61). Thus, 
these oxidized dopamine metabolites create a potentially damaging environment for 
dopaminergic neurons.   
The cells affected in PD are centers of dopamine (DA) synthesis, storage, and 
metabolism. The concentration of dopamine and its turnover within the neurons of the 
nigro-striatal pathway is very high (48). Consequently, these neurons are under an 
immense oxidative stress threat even in their resting state. Thus the intracellular 
metabolism of dopamine is a potential source of oxidative stress, capable of exerting 
toxicity by directly damaging cellular macromolecules such as proteins and DNA, and 
depleting oxidative defenses through redox cycling (57,62,63).  
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Therefore, the intent of our research is to study the redox cycling mechanism of 
dopamine oxidized metabolites and investigate the mechanism by which they cause 
oxidative stress. Our hypothesis is that the death of dopaminergic neurons in Parkinson’s 
disease is caused by oxidative stress created by redox cycling of dopamine oxidation 
products. To test this hypothesis, I pursued the following specific aims: 
I. How do redox cyclers compare in different modes of redox cycling? 
II. Does dopamine oxidize to form cytotoxic compounds capable of redox cycling? 
III. What is the underlying mechanism of cell death? 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
9 
 
CHAPTER 2 – MATERIALS AND METHODS 
Oxygen consumption assay for redox cycling 
Redox cycling was measured at 37ºC in 4 ml of 50 mM potassium phosphate, 1 
µM EDTA, pH 7.4 using a YSI Model 5300A Clark-type oxygen electrode. O2 
concentration was calibrated using glucose and glucose oxidase. Zero O2 was 
determined by injecting a sodium hydrosulfite solution into the sample chamber until no 
further decrease was observed. 
Isolation of heart mitochondria 
Mitochondria were isolated from veal heart by a modification of the method of Blair 
(64). Heart muscle (300 g) was diced and homogenized in 400 ml of 0.25 M sucrose, 0.01 
M Tris-Cl, 1 mM Tris succinate, 0.2 mM EDTA, pH 7.8 (sucrose solution) at 4°C. After 
filtering through a double layer of cheesecloth and adjusting the pH to 7.8 with 2 N KOH, 
the mince was centrifuged for 15 min at 1200 x g. The supernatant was then centrifuged 
for 15 min at 26,000 x g. The pellet was resuspended and centrifuged two more times, 
then resuspended in 10 ml of sucrose solution, divided into fractions and frozen at -40°C. 
Mitochondrial protein concentration was determined using the BCA protein assay using 
bovine serum albumin as a standard. The efficiency of the isolation procedure was 
validated by checking the succinate-dependent membrane potential as an indicator of 
mitochondrial function and integrity of the inner mitochondrial membrane. 
Fluorescence assay of NADH oxidation 
Oxidation of NADH was observed by recording the fluorescence using a Perkin 
Elmer spectrofluorometer set at an emission wavelength of 460 nm and an excitation 
wavelength of 350 nm. The fluorometer was equipped with a water-jacketed cell holder 
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that maintained the sample temperature at 37ºC. The reaction sample included 2 ml of 
phosphate buffer (pH 7.0) containing heart mitochondria and 1.25 mM KCN. NADH was 
added to a final concentration of 100 µM. After recording  a stable initial fluorescence, 
NADH oxidation was begun by adding 3-MAQ (50 µM final concentration).   
Absorbance assay of superoxide production 
Production of superoxide was measured by recording the absorbance increase 
caused by reduction of partially acetylated cytochrome c. Partially acetylated cytochrome 
c (Sigma) is reduced by superoxide but, unlike native cytochrome c, it is not a good 
substrate for mitochondrial enzymes. The assay was performed by recording absorbance 
at 550 nm on a Shimadzu UV160V spectrophotometer. The reaction mixture included 2 
ml of phosphate buffer (pH 7.2)   containing heart mitochondria, 1.25 mM KCN, and 
partially acetylated cytochrome c (100 µg/ml). After recording baseline for 25 sec, NADH 
was added to a final concentration of 500 µM.  
Preparation of HOCD and cysteinyl-dopamine 
HOCD was prepared by adding dopamine and cysteine (250 µM and 300 µM final 
concentrations, respectively) and 100 units of tyrosinase to 4 ml of F12K medium without 
serum at 37ºC. After stirring for 15 min, NaOCl was added to 1 mM. The product was 
sterilized by filtration and used immediately for experiments with PC12 cells. Cysteinyl-
dopamine was made in the same way except addition of NaOCl was omitted. 
Concentrations of these dopamine products are given as the original dopamine 
concentration. 
Measurement of cytotoxicity 
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Toxicity of redox cyclers was measured using the trypan blue exclusion assay. 
PC12 cells (ATCC Cat# CRL-1721.1, RRID: CVCL F659) were grown in six-well plates in 
F12K medium supplemented with 15% heat-inactivated horse serum, 2.5% fetal bovine 
serum and 1% penicillin/streptomycin/glutamine at 37°C and 5% CO2. Cysteinyl-
dopamine (cysDA) and HOCD were prepared in F12K medium without serum, filter-
sterilized and then diluted to the desired concentration with complete medium. Cells at a 
density of 105/ml were treated with cysDA and HOCD. After the desired treatment time, 
cells were detached using 0.1% trypsin, centrifuged, and resuspended in 0.2% trypan 
blue in Hanks Buffered Salt Solution (HBSS). After 10 min, cells were placed in a 
hemocytometer and live and dead cells were counted.  
Western blotting 
Cells were lysed using triple detergent lysis buffer with protease inhibitor (S8820, 
Sigma). The lysis buffer included 50 mM Tris, 150 mM NaCl, 0.1% SDS, 1% IGEPAL and 
0.05% deoxycholate. Protein concentrations of whole cell lysates were determined using 
the Bio-Rad DC protein assay reagent in accordance with the manufacturer’s protocol. 
For each cell lysate, 20 µg of protein was mixed in an equal ratio (1:1) with 1X SDS 
sample buffer and denatured at 95°C for 10 minutes. Denatured samples were then 
resolved by standard SDS PAGE using 8% polyacrylamide gel. Proteins were transferred 
(semi-dry) on to PVDF membranes (88518, Thermo Scientific) as described by Canelle 
et al. (65). Primary antibodies used to probe the blots were: MPO (1:250, ab65871, 
Abcam), p53 (1:500, ab131442, Abcam), caspase-9 (1:400, ab2325, Abcam), PARP 
(1:4000, #9542, Cell Signaling) and GAPDH (1:8000, MAB374, Millipore). Corresponding 
HRP-conjugated secondary antibodies used were as follows: goat anti-rabbit IgG 
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(ab6721, Abcam) and sheep anti-mouse IgG (NA931, GE Healthcare). The antibody 
signals were detected using the ECL Prime Western Blotting detection agent (Amersham, 
GE Healthcare). Blots were photographed using the FOTO/Analyst Investigator 
(FOTODYNE) and quantified using the TotalLab TL 100 software (Nonlinear Dynamics). 
Quantified values of the test protein were normalized to the loading control, GAPDH.  
Myeloperoxidase chlorination activity assay 
Chlorination activity of myeloperoxidase in whole cell lysates was determined 
using the EnzChek Myeloperoxidase (MPO) Activity Assay Kit (E33856, ThermoFisher 
Scientific). The assay was performed as per the manufacturer’s protocol. Chlorination 
activity was measured as fluorescein yielded by the selective cleavage of non-fluorescent 
3’-(p-aminophenyl) fluorescein (APF) by hypochlorite. The fluorescence intensity was 
measured with excitation at 485 nm and emission at 530 nm, using a SpectraMax Gemini 
XPS plate reader (Molecular Devices).  
Observation of superoxide production using MitoSOX 
PC12 cells were incubated in Hanks Buffered Salt Solution (HBSS) containing 
MitoSOX RedTM (2.5 µM final concentration) for 10 min at 37ºC. The buffer with MitoSOX 
dye was aspirated, cells were washed twice with fresh HBSS and placed in an Olympus 
IX81 ZDC inverted microscope equipped with a custom-built incubator for live-cell 
imaging. Bright-field and fluorescence images (rhodamine filter set) were acquired at 
37°C. Redox cycler in 1 ml of HBSS prewarmed to 37ºC was added to initiate superoxide 
generation. After 5-10 minutes, another fluorescence image was obtained. A 10×/0.25 
NA CP-Achromat lens and a 40×/0.75 NA Plan-Neofluar lens were used for phase 
contrast images and fluorescence images respectively. All images were acquired with a 
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Diagnostic Instruments (MI, USA) Boost EM-CCD-BT2000 camera driven by IPLab 
software (BD Biosciences, MD, USA). Images were optimized using ImageJ software.  
Statistical analysis 
An unpaired t-test was used to calculate p values. For toxicity, 9 samples in each 
group were compared (16 degrees of freedom). Myeloperoxidase activities were 
compared with 4 samples in each group (6 degrees of freedom) and myeloperoxidase 
expression with 3 (4 degrees of freedom). Significance is indicated as ns (p ≥ 0.05), *(p 
< 0.05), **(p < 0.01), ***(p < 0.001), ****(p < 0.0001). 
Materials   
Myeloperoxidase (EMD Millipore) was dissolved in pH 6 phosphate buffer at a 
concentration of 0.33 mg/ml. Sodium hypochlorite (140 mM) was prepared by mixing 
0.375 g of calcium hypochlorite with 1.0 g of sodium carbonate in 25 ml of H2O and 
removing the precipitate by filtration. Hypochlorite was assayed by the method of Han et 
al. (66). 3-Methyl-5-anilino-o-quinone (3MAQ) was synthesized by oxidizing 3-
methylcatechol in the presence of aniline (67). Mushroom tyrosinase, bovine liver 
catalase, superoxide dismutase, menadione, 6-hydroxydopamine and 9,10-
phenanthrenequinone were purchased from Sigma/Aldrich and MitoSOX Red from Life 
Technologies. 
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CHAPTER 3 – REDOX CYCLING 
INTRODUCTION 
Oxidation/reduction (redox) reactions, as the name suggests, involve both 
reduction and oxidation. They are chemical reactions in which one or more electrons are 
transferred between two compounds. This electron transfers either results in an increased 
oxidation state (oxidation) of a molecule due to the loss of electrons or a decreased 
oxidation state (reduction) of a molecule due to the gain of electrons. The oxidized and 
reduced forms of the same molecule are together called a redox couple. Redox reactions 
typically occur in pairs, one redox couple being reduced and the other being oxidized. 
The tendency of a molecule to either donate or accept electrons reflects its 
reduction potential. The standard reduction potential (E0) of a molecule is determined by 
comparing its value to that of hydrogen, which is arbitrarily set at zero. Thus, strong 
oxidizing agents have positive redox potentials whereas reducing agents have negative 
redox potentials. The difference in reduction potential between two molecules will 
determine the equilibrium between their oxidized and reduced states. Redox couples with 
lower reduction potentials will donate electrons to reduce redox couples with higher 
potentials. When many different redox active intermediates are present, redox reactions 
often occur as a chain of successive redox reactions.  
Regulating redox activities is imperative for the control of several cellular signaling 
pathways. Thus, in order to define different processes in redox biology, it is not only 
necessary to understand the chemistry underlying the redox reactions but also appreciate 
the biological context that supports these reactions. Factors such as concentration, 
pressure, pH and temperature affect the redox potential of a molecule.  
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There are many redox couples that contribute towards maintaining the redox 
environment, a prominent one being the abundantly found GSSG/2GSH couple 
(glutathione). The half-cell reduction potential (Ehc) of the GSSG/2GSH couple varies 
according to the biological status of the cell; during proliferation Ehc ~ -240 mV; during 
differentiation Ehc ~ -200 mV; or during apoptosis Ehc ~ - 170 mV (68). These potentials 
are useful in deducing the redox status and associated oxidative stress in a cell. Using 
this approach of quantitative biology thereby offers a rationale to explore the cellular 
mechanisms involved with cell growth and development, signaling, oxidative stress and/or 
apoptosis.  
Reduction potential is an important parameter for reactions involving redox active 
metabolites. However, under physiological conditions, redox couples are rarely in 
equilibrium. The concentrations of reduced and oxidized forms are subject to constant 
variation due to fluctuating enzyme concentrations and activities, as the result of 
metabolism. The degree of redox activity in a cellular environment, at any point of time, 
depends on the physiological condition in conjunction with the number and state of the 
redox active moieties involved.  
Redox cycling involves continuously coupled reduction and oxidation reactions, 
often involving oxygen and reactive oxygen species. In theory, any compound with the 
tendency to accept or donate electrons can participate in redox cycling. Redox reactions 
are reversible and most redox active compounds can be either oxidants or reductants 
depending on the biological conditions. Redox-cycling occurs when a compound 
undergoes alternating reduction and oxidation reactions.   
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In the first step of redox cycling, the redox cycler undergoes reduction in the 
presence of a reducing agent. Re-oxidation of the reduced form takes place most 
significantly in the presence of molecular oxygen. The intermediate donates a single 
electron to oxygen thereby reducing it to the superoxide radical anion. This will result in 
the regeneration of the original parent compound in addition to the superoxide anion. The 
reduction of O2 to superoxide is especially significant because it occurs spontaneously 
(non-enzymatically) by outer-sphere electron transfer and it yields the highly reactive 
superoxide. Superoxide generation further leads to the formation of hydrogen peroxide 
either spontaneously or by the catalytic action of superoxide dismutase. If hydrogen 
peroxide encounters transition metals under physiological milieu, it can be converted to 
highly toxic and potentially damaging hydroxyl radical and singlet oxygen (69,70). Thus, 
redox cycling leads to the proliferation of a variety of reactive oxygen species. 
Redox cycling compounds, based on their redox potential, can accept electrons 
from biologically available reducing agents such as reduced flavoproteins, NADPH, 
NADH, reduced ferredoxin, reduced glutathione (GSH) and other thiol containing 
compounds and ascorbic acid. Under physiological conditions, some enzymes are also 
known to catalyze such reactions. These include NADPH-cytochrome P-450 reductase, 
xanthine oxidase, mitochondrial flavoproteins of the electron transport chain and many 
other dehydrogenases (69,70). 
The process of redox cycling involving these alternating reduction and oxidation 
reactions continues until the molecular oxygen and/or reducing equivalents are 
exhausted. This process is sometimes also referred to as “futile cycling.” This process of 
redox cycling could eventually lead to cytotoxicity via depletion of essential reducing 
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equivalents, depletion of oxygen or via potential interaction between free radicals and 
critical biological macromolecules (69,70). Radicals released during redox cycling can by 
themselves engage in free radical-mediated toxic reactions. They have the tendency to 
bind covalently to macromolecules and cause lipid peroxidation, DNA damage or protein 
inactivation. Moreover, interaction of free radicals with smaller biomolecules such as 
glutathione could be equally damaging. Glutathione is not only an integral cellular defense 
against cytotoxic agents but also plays a major role in other biological functions such as 
deoxyribonucleotide synthesis. During redox cycling, glutathione tends to compete with 
molecular oxygen for anion radicals, which leads to depletion of the reduced form of 
glutathione. Based on the degree of release of free radicals, it could also lead to 
disorganization of membrane structure and ultimately disruption of cytoskeleton and cell 
death.  
Under conditions of relatively high molecular oxygen, toxicity could result due to 
the generation of hydroxyl radicals or from the depletion of important reducing agents. On 
the contrary, under low oxygen levels, induction of a hypoxic state and/or an increase in 
the organic radical levels are the predominant causes of toxicity (69). From an 
experimental perspective, redox cycling and its subsequent ROS generation tend to 
interfere with enzymes or reagents in biochemical assays and high throughput screens 
giving false positive results (71-73). 
Redox cycling of quinones has been a well-studied phenomenon and its 
connection to toxicity has been firmly established (74). Quinones have a tendency to 
undergo one- or two-electron reduction reactions. In the case of the former, radical 
semiquinones are formed and due to their highly unstable nature, one-electron reduction 
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generates reactive species (69,70). Two-electron reduction on the other hand, mostly 
catalyzed by diaphorases, results in the formation of completely reduced and biologically 
inactive hydroquinones. This is usually considered as a detoxification process (75,76). 
Supporting this theory, Thor et al. have shown that inhibiting DT diaphorases enhances 
the toxicity of quinones by leaving them free to undergo one-electron reduction to 
semiquinones (76). Numerous redox cycling compounds have been reported to have 
deleterious biological effects due to their conversion to quinones and semiquinones. Apart 
from the quinones, there are a number of naturally occurring benzophenanthridine 
compounds such as sanguinarine and chelerythrine, that also redox cycle generating free 
radicals and leading eventually to apoptosis (77). Though a number of studies have 
focused on the link between redox cycling and toxicity, very few studies have considered 
the relation between the mode of redox cycling and toxicity. 
In the case of Parkinson’s disease, one plausible mechanism that links dopamine 
oxidation to oxidative stress, and which possibly accounts for selective loss of 
dopaminergic neurons, is the redox biochemistry specific to dopamine. Multiple pathways 
of dopamine oxidation have been identified. At physiological pH, dopamine can auto-
oxidize forming reactive oxygen species which can damage cellular constituents such as 
lipids, proteins and DNA. Auto-oxidation of dopamine can lead to the formation of 
dopamine-quinones that can easily react with cellular nucleophiles. Both in vitro and in 
vivo studies have shown dopamine-derived quinones to react with thiols of proteins. 
Within striatal nerve terminals, the concentration of dopamine has been estimated to be 
around 50 mM (78). Reports have demonstrated that increased dopamine oxidation in 
the presynaptic cleft leads to an alteration in the redox status of dopamine terminals (79). 
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With specific reference to DA being considered as an endogenous neurotoxin, two 
independent studies have established that DA quinones inactivate tyrosine hydroxylase 
by covalently modifying its sulfhydryl groups. This converts the enzyme to a redox-cycling 
quino-protein which can react with transition metals via Fenton chemistry and thereby 
cause oxidative stress and consequent dopamine synthesis failure. Compounds with low 
potentials are known to undergo redox cycling, e.g., quinones such as menadione and 
catecholamine derivatives such as 6-hydroxydopamine, adrenochrome and 
aminochrome. Redox cycling of compounds like aminochrome and adrenochrome have 
been suggested to cause the death of dopaminergic cells in Parkinson’s disease. 
However, these catecholamine derivatives have a tendency to oxidize to higher potential 
dihydroxyindoles, making them highly unstable and difficult to study their biological effects 
and redox cycling mechanism.  
Nonetheless, in regards to Parkinson’s disease it is important to consider that mild 
oxidative stress persists for years in nigrostriatal neurons, which could ultimately evoke a 
biological condition leading to untimely death of the dopamine neurons. Evidence in 
support of this has also shown traces, at autopsy, of oxidized dopamine metabolites in 
nigral neurons (63,80-82). 
Studies with biological systems have shown increased generation of hydrogen 
peroxide with cell-specific redox cycling of toxic products such as paraquat, doxorubicin 
and alloxan (83). This has led to cellular destruction and subsequent phagocytosis. 
Similarly, in brain, redox cyclers like, 6-hydroxydopamine and 6-aminodopamine have 
been shown to specifically damage catecholamine neurons (84). Also, in addition to 
hydrogen peroxide, other species including hypochlorous acid, reactive quinones, 
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hydroxyl radicals and superoxides have also been shown to contribute to the stress in 
dopamine nerve terminals. 
Redox cycling compounds are prooxidant catalysts that transfer electrons to 
oxygen to generate reactive oxygen species (75,76). Commercially, such compounds are 
used as substituents in xenobiotic compounds (e.g. redox active pesticides) (85-89), 
redox active pharmacophores (e.g. anesthetics) (90) and in pharmaco chemotherapeutic 
drugs (e.g. menadione, doxorubicin/adriamycin) (91-94). Studies have shown that an 
inability to detoxify the redox cycling agents has led to increased vulnerability to 
environmental hazards. From a pharmaceutical perspective, this has also introduced 
some limitations in anticancer chemotherapeutics and antibiotics. Since there may be an 
age-related decline in the capacity to detoxify redox cycling compounds, it is extremely 
important to have detailed toxicity profiles of such redox cyclers from a therapeutic point 
of view.   
Therefore, the aim of this study is to understand the different modes of redox 
cycling by comparing chemically synthesized redox cyclers. 
RESULTS 
Over the years, consumption of oxygen and production of superoxide anions have 
been used for measuring redox cycling activities. For our experimental purposes, we 
employed a convenient assay to study redox cycling, where we measure oxygen 
consumption using a Clark-type oxygen electrode. The rate of oxygen consumption is 
directly proportional to the redox cycling activity of the compound studied. The 
compounds used in our work were 9,10-phenanthrenequinone, menadione, 6-hydroxy 
dopamine and 3-methyl-5-anilino-1,2-benzoquinone. Among these, 3-MAQ is a 
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chemically synthesized, laboratory developed redox cycler that structurally mimics and 
shares some electrochemical properties with the oxidized dopamine metabolite 
aminochrome. The others are commercially available chemically synthesized 
compounds.   
To study the redox cycling process, ascorbic acid and dithiothreitol (DTT) were 
used as reducing agents. Both ascorbate and DTT were used to catalyze non-enzymatic 
reduction of the redox cyclers. As observed in fig. 2, all four compounds did undergo 
ascorbate- as well as DTT-dependent redox cycling.  
When ascorbic acid is used as an electron donor, one-electron reduction of the 
redox cycler takes place (Fig. 1). As a result, the quinone is reduced to a semiquinone 
radical and ascorbate is oxidized to semidehydroascorbate. The semiquinone reacts with 
O2 yielding superoxide and the oxidized quinone. The superoxide produced in this 
scenario reacts with ascorbate as well as semidehydroascorbate. Thus, when superoxide 
dismutase is added alongside ascorbic acid, there is no effect on the redox cycling 
activity. 
DTT is a strong reducing agent that usually catalyzes two-electron reduction 
reactions. It tends to reduce the quinone redox cycler by donating two electrons to form 
a hydroquinone (Fig. 1). The relatively stable hydroquinone does not react readily with 
O2, so it must be oxidized by superoxide. The semiquinone formed in this first step is then 
oxidized back to its parent quinone by molecular oxygen. This second step generates the 
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Figure 1. One-electron vs. two-electron mediated redox cycling – Ascorbic acid 
mediates one-electron reduction forming the semi-quinone (Q-); dithiothreitol mediates 
two-electron reduction forming the fully reduced hydroquinone (QH2). Whereas O2 
oxidizes the reactive semiquinone, superoxide is required to oxidize the hydroquinone. 
 
superoxide anions needed for the first step. Thus, when superoxide dismutase is added 
to the solution along with DTT, redox cycling is inhibited. This is because superoxide 
dismutase eliminates superoxide anions from the solution, inhibiting the conversion of 
hydroquinone to the semiquinone anion. Because some superoxide is undoubtedly lost 
by disproportionation and reaction with DTT, there must be other mechanisms for 
converting the corresponding fraction of hydroquinone to the semiquinone. Otherwise, 
the hydroquinone would accumulate and redox cycling would stop. There could be a 
comproportionation reaction in which the hydroquinone and quinone forms of the redox 
cycler react to form the semiquinone radical anion. The hydroquinone might also react 
slowly with O2, especially in the case of low-potential redox cyclers. 
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Figure 2. Inhibition of ascorbate and dithiothreitol-driven redox cycling by 
superoxide dismutase – Redox cycling was monitored as O2 consumption at 37 °C and 
pH 7.4, in a Clark-type oxygen electrode. The redox cycling activity of varying 
concentrations of (A) 3-MAQ; (B) 9,10-Phenanthrenequinone; (C) Menadione; and (D) 6-
hydroxydopamine, was initiated by adding 2.5 mM ascorbic acid (green) or 250 µM 
dithiothreitol (blue). Superoxide dismutase when added; inhibited the redox cycling 
activity with dithiothreitol (red) as the electron donor but had no effect with ascorbate 
(purple) as the electron donor. 
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Of the four redox cyclers tested, it is apparent that DTT-driven redox cycling of 
menadione is less sensitive to superoxide dismutase. This may be because menadione 
comproportionates faster than the other compounds or that its hydroquinone reacts more 
readily with O2. Menadione does have the lowest reduction potential of the redox cyclers 
tested (-5 mV compared to +10 mV to +90 mV for the others). 
6-Hydroxydopamine (6-OHDA) is an endogenous neurotoxin formed by dopamine 
oxidation, and it is commonly used as a dopaminergic neurotoxin to mimic the effects of 
Parkinson’s disease. It was tested here to characterize the redox cycling mechanism of 
this oxidized dopamine metabolite. 6-Hydroxydopamine is highly unstable in aqueous 
solution, and it spontaneously reacts with molecular oxygen changing a colorless solution 
to bright red, with a maximum absorbance at 490 nm. This is due to the formation of the 
quinone form of 6-OHDA. Interestingly, addition of DTT immediately changes the solution 
to colorless, suggesting rapid reduction of the quinone back to the fully reduced 6-OHDA 
in a two-electron reduction. In the case of ascorbate, this change is gradual. This suggests 
that ascorbate reduces the 6-OHDA quinone to the semiquinone in a one-electron 
reduction. The semiquinone then rapidly reoxidizes by reacting with O2.  
While ascorbic acid is a good reducing agent for redox cycling in vitro, it is also a 
good antioxidant so oxidative stress will be minimal in its presence. Therefore, it is 
imperative to find another natural cellular reducing mechanism that will permit oxidative 
damage. Enzymatic reduction is likely, and the mitochondria are of particular interest 
because of their high and continuous production of reduced electron carriers (i.e. NADH 
and FADH2).  
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Mitochondria-driven redox cycling of 3-MAQ was checked using a Clark-type 
oxygen electrode (Fig. 3). Potassium cyanide was added to eliminate any interfering O2 
consumption catalyzed by the respiratory chain in the mitochondria. Typically, this 
interference was small, however, as eliminating KCN from the reaction sample yielded 
similar results. After 5 minutes, either 40 μl of 10 mM 3-MAQ or 40 μl of 50 mM reduced 
nicotinamide adenine dinucleotide (NADH) was added, followed 5 minutes later by the 
addition of the other. The redox cycling activity of 3-MAQ was measured as the rate of 
oxygen consumption. Addition of only 3-MAQ did not show any redox cycling activity 
indicating the absence of any endogenous NADH. Also, eliminating mitochondria 
diminished the redox activity. This confirmed the need for both mitochondria and NADH 
in the redox cycling of 3-MAQ 
 
Figure 3. NADH-dependent redox cycling in veal mitochondria – The reaction mixture 
containing 4 ml of phosphate buffer (pH 7.0), 100 µl of veal brain mitochondria and 50 µl 
of 100 mM potassium cyanide (KCN) was placed in the oxygen electrode chamber at 
37°C. 3-MAQ (100 µM final concentration) was added at time = -5 min and 50 mM NADH 
(500 µM final concentration) was added at time = 0. The redox cycling activity of 3-MAQ 
was observed as the consumption of oxygen. It was not observed in the presence of 50 
µl of 50 mM NAD+ or 40 µl of 250 mM mersalyl acid, or in the absence of mitochondria. 
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Once the redox cycling of 3-MAQ was found to be NADH-dependent, we confirmed 
the oxidation of NADH by looking at the NADH fluorescence during redox cycling (Fig. 4). 
Fluorescence of NADH was recorded using a Perkin Elmer spectrofluorometer set at an 
emission wavelength of 460 nm and an excitation wavelength of 350 nm. Addition of 10 
μl of 10 mM 3-MAQ, oxidized the NADH, as seen by the linear decrease in fluorescence. 
The immediate drop in fluorescence following 3-MAQ addition is an artifact caused by the 
absorbance of 3-MAQ. 
 
 
Figure 4. Oxidation of NADH during redox cycling of 3-MAQ – NADH was measured 
by fluorescence. The reaction sample included 2 ml of phosphate buffer (pH 7.0), 20 µl 
heart mitochondria and 25 µl of 100 mM KCN. 40 µl of 5 mM NADH was added at -6 min. 
Addition of 10 µl of 10 mM 3-MAQ at time = 0 initiated oxidation of NADH confirmed by 
the drop in the fluorescence readings. NADH oxidation was inhibited in the presence of 
20 µl of 250 mM mersalyl acid and when mitochondria were omitted. 
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Inhibitors of various mitochondrial functions including the respiratory chain 
(rotenone, cyanide, quercetin, antimycin), xanthine oxidase (allopurinol) and 
NADH:quinone oxidoreductase (dicumarol) were tested for inhibition of the redox cycling 
activity of 3-MAQ (data not shown). None, except mersalyl acid, inhibited NADH-
dependent redox cycling (Fig. 3). Mersalyl acid seemed to inhibit the redox cycling activity 
of 3-MAQ almost completely. Mersalyl acid is known to inhibit cytochrome b5 reductase. 
This hints at the possibility that cytochrome b5 reductase could be the primary 
mitochondrial enzyme that catalyzes the redox cycling of oxidized dopamine products (3-
MAQ in this case). To test this possibility, we examined the effect of cytochrome b5 on 3-
MAQ redox cycling in the oxygen electrode. Human recombinant cytochrome b5 (20 
µg/ml final concentration) was added to the oxygen electrode in 4 ml of 0.2 M phosphate 
buffer (pH 7.0) containing heart mitochondria, cyanide and 3-MAQ (100 µM final 
concentration). Redox cycling was initiated by adding NADH (0.5 mM final concentration).  
Presence of cytochrome b5 increased the redox cycling activity of 3-MAQ, as 
indicated by a noteworthy increase in the rate of oxygen consumption (Fig. 5). Although 
there is an apparent increase in 3-MAQ redox cycling due to cytochrome b5, what role it 
plays in this mechanism and how it interacts with cytochrome b5 reductase in this 
experiment is still not clear.  
Of special interest is whether NADH-driven redox cycling of 3-MAQ produces 
superoxide in the presence of mitochondria. This was checked by assaying superoxide 
using acetylated cytochrome c (95). Acetylated cytochrome c is readily reduced by 
superoxide but is relatively less susceptible to direct reduction by mitochondrial enzymes 
than the native protein, thereby providing less interference from competing reactions.  
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Figure 5. Effect of cytochrome b5 on NADH-dependent redox cycling – Redox 
cycling of 3-MAQ (100 µM final concentration) was tested in the oxygen electrode in the 
presence and absence of 40 μl of human recombinant cytochrome b5 (1mg/ml); NADH 
(500 µM final concentration) was also added at time=0. The presence of cytochrome b5 
caused a noteworthy increase in the rate of oxygen consumption. 
 
 
Figure 6. Superoxide production observed by cytochrome c reduction – Cytochrome 
c reduction was recorded at 550 nm. The reaction mixture including 2 ml of mitochondrial 
assay buffer (pH 7.2), 10 µl of veal heart mitochondria, 25 µl of 100 mM KCN and 20 µl 
of acetylated cytochrome c was placed in a cuvette and absorbance was recorded for 2 
minutes. 20 µl of 50 mM NADH was added at time = 25 sec. 10 µl of 2.5 mM 3-MAQ when 
added, caused the production of superoxide anions, whereas presence of 20 µl of 3000 
U/ml of superoxide dismutase decreased the production of superoxide anions. 
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The assay was performed by recording the cytochrome c reduction as the increase in 
absorbance at 550 nm. As predicted, superoxide production was observed with 
acetylated cytochrome c, as detected by the decrease in absorbance (less cytochrome c 
reduction) when superoxide dismutase was present (Fig. 6). 
DISCUSSION 
 It is generally believed that one-electron reduction generates reactive oxygen 
species whereas two-electron reduction leads to detoxification (69,70). One-electron 
reduction reactions are mediated by a number of reductive enzymes, namely, microsomal 
NADPH-cytochrome P450 reductase and mitochondrial NADH-ubiquinone 
oxidoreductase (complex I) (96). The unstable semi-quinone formed in the process can 
readily be oxidized by molecular oxygen, resulting in reformation of quinone and 
generation of reactive oxygen species. In contrast, two-electron reduction of quinones is 
catalyzed by reductive enzymes, such as NAD(P)H:quinone oxidoreductase 1 (EC 
1.6.99.2, NQO1; DT-diaphorase), where the resulting hydroquinone is comparatively 
more stable than the semi-quinone (97). Thus generation of ROS is greatly diminished. 
These two cases are analogous to the two-electron dithiothreitol- and one-electron 
ascorbic acid-dependent redox cycling mechanisms respectively. Can general principles 
derived from in vitro studies of redox cycling be applied to understand observations in 
vivo? The inhibition of dithiothreitol-dependent redox cycling by superoxide dismutase 
implies that two-electron reduction of quinones is protective only as long as superoxide 
concentrations are kept low. If superoxide increases, it will oxidize the reduced quinones 
to their more reactive semiquinones. 
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Among the redox cyclers that we studied, menadione is an interesting special 
case. It has been previously shown to induce lipid peroxidation and membrane damage 
and to decrease reduced glutathione levels due to its redox cycling capability (76,98-101). 
Criddle et al. (2006) have shown that redox cycling of menadione generates reactive 
oxygen species and leads to apoptotic cell death of pancreatic acinar cells (97). They 
also showed that redox cycling of menadione led to a concomitant decrease of NAD(P)H, 
thereby hindering the activity of two-electron detoxifying enzymes such as 
NAD(P)H:quinone oxidoreductase. In my in vitro studies, menadione is actually a 
relatively slow redox cycler compared to the other compounds. However, its DTT-
dependent redox cycling is also relatively insensitive to superoxide dismutase. Thus, 
menadione may be unexpectedly effective in vivo because it can redox cycle in the 
presence of two-electron quinone reduction and low superoxide levels.    
Redox cycling quinones have been implicated in many forms of neurotoxicity 
(102,103). When a quinone undergoes one-electron reduction, a semiquinone is 
generated. This semiquinone gets converted back to its parent quinone form by donating 
one electron to dioxygen (104). Redox cycling of quinones is tightly restricted. If a quinone 
is a strong oxidant then semiquinone formation is favored, but not the regeneration of the 
parent compound. If a quinone is a strong reductant, then reaction of the semiquinone 
with oxygen is favored, but not the formation of the semiquinone. A good redox cycler, 
therefore, is ideally a compound that can be easily oxidized and can then be reduced 
back to its original form. They typically have reduction potentials in the range of -100 mV 
to +100 mV. Some of the organic chemical compounds capable of undergoing one-
electron reduction and redox cycling are azo derivatives, nitroso compounds, N-oxides, 
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S-oxides and polyhalogenated aliphatic hydrocarbons. Contrarily, carbonyl compounds 
do not favor generation of radical intermediates, because they undergo dehydrogenase-
catalyzed two-electron mediated reduction reactions. Physiological conditions are ideal 
for the reduction and redox cycling of these compounds, since live cells have strongly 
negative reduction potentials (69,70).  
Quinones are electron-deficient compounds which are highly reactive with 
nucleophilic groups such as thiols and protein sulfhydryls (105). In vivo, therefore, 
quinones can react with and covalently link to proteins. Antioxidants and reductants can 
protect against quinone-induced damage by competing with protein sulfhydryls for the 
quinones (61,106-108). Interestingly, the rate of redox cycling can be more pronounced 
when the quinone is bound to a protein rather than in its free form in solution. In support 
of this conclusion, the effects of quinoproteins have been found to last longer than those 
of reactive oxygen species or quinone by itself, in solution (61,106,109). Also, 
antioxidants, that usually serve as cellular defense mechanisms protecting against 
oxidative stress, have been reported to contribute to redox cycling of a protein bound 
quinone, which also depletes cellular energy and endogenous reducing equivalents 
(103,110,111).  
Some compounds have been proposed to redox cycle in vivo although they do not 
redox cycle in vitro. In the MPTP model for Parkinson’s disease, MPTP is converted to its 
more toxic compound MPP+. Neither MPTP nor its oxidized counterpart can redox cycle. 
MPTP itself is highly stable under normal conditions and does not autoxidize. When 
MPTP undergoes two-electron as well as four-electron oxidation, neither of the oxidation 
products of MPTP can be reduced easily (112). Chacon et al. (1987) showed that the 
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reduction potential of MPP+ (-1V) at physiological pH makes it a poor redox cycling agent 
(113).  Nevertheless, it has still been suggested that MPP+ gets reduced to the MPP 
radical, which undergoes redox cycling (114). Whether MPP+ leads to oxidative stress 
via redox cycling is still an unanswered question.  
Paraquat, a well-known herbicide, is structurally similar to MPP+ and has been 
widely used to study Parkinson’s disease. Animal models chronically treated with 
paraquat have demonstrated loss of dopaminergic neurons in the substantia nigra. The 
toxicity of paraquat has been attributed to its ability to redox cycle (115). It has a reduction 
potential of -0.450 V, which is significantly higher than that of MPP+ but still very low for 
a redox cycler. Some studies have questioned the redox cycling capability of paraquat. 
In an assay for redox cycling, paraquat did not produce hydrogen peroxide and therefore, 
levels of reactive oxygen species were low (116). 
How compounds that fail to redox cycle in vitro can appear to do so in vivo is 
therefore a mystery. Whether they metabolize to other redox cycling compounds, couple 
to proteins to form redox cycling adducts, or inhibit activities that allow the redox cycling 
of endogenous compounds are all possibilities. There are numerable factors that 
determine the amount of biologically active, reactive intermediates formed by redox 
cycling. Among the two major factors involved, one is the redox potential of the compound 
to be reduced and another is the availability and activity of the enzymes catalyzing the 
reduction reactions. The energy status as well as the oxygen tension of the affected cell 
population also impact the redox cycling process (69,70). Another factor that influences 
the equilibrium reaction of a redox cycler with oxygen is superoxide dismutase. 
Superoxide dismutase catalyzes dismutation of superoxide to hydrogen peroxide and 
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water further driving the reaction towards radical formation. Other variables that may 
affect the redox cycling mechanism under certain conditions are the availability of 
reducing equivalents and cellular concentrations of antioxidants (69,70). 
Although redox cycling has been a well-studied phenomenon in vitro, inconsistent 
observations in vivo have remained a persistent challenge for the research community. It 
is important to consider the translational gap that exists between in vitro and in vivo 
studies. A compound capable of redox cycling and producing free radicals in vitro, may 
not follow suit in vivo (117). As a first step towards narrowing this gap, it is necessary to 
demonstrate the generation of free radicals in vivo (117). A thorough understanding of 
the structural and physicochemical aspects of redox cycling is required. This would further 
help in generating compounds, capable of influencing cellular redox status, with 
therapeutic applications. 
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CHAPTER  4 – DOPAMINE, HYPOCHLORITE AND PARKINSON’S DISEASE 
INTRODUCTION 
The dopamine oxidation pathway has been studied extensively.  Dopamine is 
usually sequestered in to intracellular vesicles that prevent it from oxidizing under the 
physiological conditions of the cytosol. In PD patients, it has been reported that the 
activities of vesicular monoamine transporter 2 (VMAT2) (118) and the cell membrane 
dopamine transporter (DAT) (119) are diminished, so the possibility of free dopamine in 
cytosol/synapses increases considerably. Free dopamine that has escaped or been 
released from this vesicular storage, whether in the cytoplasm of the cell or in the 
synapse, is more likely to undergo either enzymatic or non-enzymatic oxidative 
metabolism to deleterious species that exert cytotoxicity through a variety of established 
mechanisms (53,57). Among dopamine metabolites, 3,4-dihydroxyphenylacetaldehyde 
(DOPAL), aminochrome, 5-S-cysteinyl dopamine and its metabolite DHBT-1 have all 
received considerable attention.  
Enzymatically, dopamine is metabolized oxidatively by monoamine oxidase (MAO) 
and catechol-o-methyltransferase. MAO-B, an outer mitochondrial membrane enzyme, 
catalyzes oxidative deamination of dopamine to 3,4-dihydroxyphenylacetaldehyde 
(DOPAL) which is more toxic than the parent dopamine (120). DOPAL itself can be 
converted to a comparatively non-toxic compound DOPAC by aldehyde dehydrogenase 
(ALDH). In Parkinson’s patients, DOPAL is found to be selectively toxic to dopaminergic 
neurons while ALDH activity is reduced (120). Interestingly monoamine oxidase inhibitors, 
which would be expected to block the formation of DOPAL, do not appear to slow the 
progression of Parkinson’s disease. Also, within astrocytes, dopamine can be 
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metabolized into homovanillic acid (HVA) through the synergistic action of catechol-o-
methyltransferase (COMT), monoamine oxidase (MAO) and aldehyde dehydrogenase 
(ALDH) (121,122). Dopamine may also undergo oxidation via minor enzymatic pathways, 
involving the enzymes prostaglandin H synthase, lipoxygenase, and tyrosinase (123).  
Our study, however, focuses on the non-enzymatic oxidation of dopamine and its 
auto-oxidation metabolites. Dopamine can undergo non-enzymatic spontaneous auto-
oxidation to radicals and quinones, with concomitant release of reactive oxygen species 
(53-56). To begin the non-enzymatic oxidation, dopamine auto-oxidizes slowly in the 
presence of O2 to form the o-quinone. The o-quinone is susceptible to nucleophilic attack, 
and reacts rapidly with thiols such as cysteine, to form adducts such as 5-S-cysteinyl-
dopamine (55,61).  
Since cysteine residues play an important role in protein function, their modification 
via the irreversible covalent reaction between dopamine quinone and cysteine can have 
adverse effects on cellular health (60). Moreover, the basal level of oxidative stress rises 
in the neurons, due to the formation of the conjugate quinone species, especially as 5-S-
cysteinyl species are more easily oxidized than the parent catecholamine. Notably, traces 
of 5-S-cysteinyl-dopamine have been detected in the cerebrospinal fluid of PD patients, 
dopamine-rich regions of the brain such as the caudate nucleus, putamen, globus pallidus 
and substantia nigra, and in neuromelanin (81,124).  
Cysteinyl-dopamine has been reported to kill neuronal cells (82), but it is uncertain 
whether it is cytotoxic itself or metabolizes to toxic products. Cysteinyl-dopamine oxidizes 
relatively slowly like dopamine itself.  In an effort to identify products that react more 
quickly with O2 and therefore would generate reactive oxygen species (ROS), we have 
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sought dopamine metabolites capable of  rapid redox cycling. We report here that 
hypochlorite converts cysteinyl-dopamine into a cytotoxic redox cycling product capable 
of generating free radicals and thereby creating oxidative stress.  
RESULTS 
 Over the years, a number of studies have shown that cysteinyl-dopamine (cysDA) 
is toxic to a variety of neuronal cells and cell lines in culture (82,125-127). Here, we found 
that cysteinyl-dopamine at concentrations of 100 μM or greater is toxic to 
catecholaminergic PC12 cells (Fig. 8). When cysDA is oxidized with hypochlorite, PC12 
cells are more susceptible to the resulting product at lower concentration; the same 
concentration of hypochlorite by itself is not toxic. Interestingly, addition of taurine to the 
cells nearly abolishes the toxicity of cysDA for up to 48 hours but has no effect on the 
toxicity of the hypochlorite-treated product. Taurine is known to be a hypochlorite 
scavenger (128), suggesting that the toxicity of cysteinyl-dopamine may depend upon its 
conversion to the hypochlorite product. This product is suspected to be a benzothiazine 
derivative (see discussion), but as the structure is not yet established, we will refer to it 
as HOCD (hypochlorite-oxidized cysteinyl-dopamine). 
Hypochlorite Converts Cysteinyl-dopamine into a Redox Cycling Product 
There have been reports suggesting that cysteinyl-dopamine causes oxidative 
stress (82,125). To investigate this, we tested cysteinyl-dopamine and HOCD for redox 
cycling activity.  A  convenient  assay  for  determining  the  redox  cycling  activity  is   to  
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Figure 7. Non-enzymatic dopamine oxidation reactions – HOCD and HOCDSQ are 
the oxidized and semi-quinone forms of the redox cycling compound formed by reaction 
of cysteinyl-dopamine with hypochlorite. 
 
measure the rate of ascorbate-dependent oxygen consumption using a Clark-type oxygen 
electrode. The compound is reduced by ascorbic acid and re-oxidized by molecular 
oxygen. To recapitulate the dopamine oxidation process, dopamine oxidation was 
accelerated using tyrosinase to form the o-quinone. This produces cysteinyl-dopamine in 
the presence of cysteine and aminochrome in its absence. Using the ascorbic acid-
dependent oxygen consumption assay, redox cycling is not observed when 25 μM 
dopamine is oxidized by tyrosinase in the presence of cysteine unless hypochlorite is 
present (Fig. 9A). Cysteinyl-dopamine itself therefore is not effective at redox cycling, but 
is efficiently converted into a redox cycling product when oxidized by hypochlorite. In the 
presence of hypochlorite, all of the O2 in the solution is consumed within minutes after 
adding an excess of ascorbic acid. Since the oxygen concentration exceeds that of  
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Figure 8. Taurine reduces toxicity of cysteinyl-dopamine but not of HOCD in PC12 
cells – PC12 cells were treated with cysteinyl-dopamine or HOCD at the indicated 
concentrations and both live and dead cells were counted after 24, 48 or 72 h. Dashed 
lines show the effect of 25 mM taurine added to the medium. Each point is the average 
(± standard deviation) of nine replicate samples. For cysteinyl-dopamine (A, B and C), 
survival with taurine was significantly greater than survival without taurine with p < 0.0001 
in all cases except 50 μM cysDA at 24 h (p=0.054) and 48 h (p=0.023) as indicated. For 
HOCD (D, E and F), survival with taurine was not significantly different from without 
taurine (p > 0.05) except for 200 μM HOCD at 72 h (p=0.018). 
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Figure 9. Conversion of dopamine into redox cycling products by hypochlorite – 
(A) Redox cycling was monitored as O2 consumption at 37 °C and pH 7.4. Redox cycling 
products were formed by adding dopamine (25 μM), cysteine (37.5 μM) and tyrosinase 
(100 units) followed by the indicated concentration of sodium hypochlorite. Redox cycling 
was initiated by adding 2.5 mM ascorbic acid. (B) Rate of redox cycling by dopamine 
oxidation products. Rates were determined from the initial slope following ascorbic acid 
addition from recordings obtained as in A using 100 μM sodium hypochlorite. Catalase 
(100 μg) was added to the indicated sample at the same time as ascorbic acid. For each 
of the other conditions, indicated components were omitted (cysteine and sodium 
hypochlorite were both omitted from DA+Tyrosinase). Bars show the average ± standard 
deviation of three replicate samples. 
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dopamine by a factor of ten, the dopamine product must be cycling, alternately reduced 
by ascorbic acid and oxidized by O2. Detectable redox cycling may be observed with 
hypochlorite concentrations as low as a few micromolar. Dopamine treated with 
tyrosinase in the absence of cysteine produces aminochrome which has weak redox 
cycling activity (Fig. 9B). This is observed both in samples with no cysteine and in those 
with just dopamine and tyrosinase. Dopamine like cysteinyl-dopamine has no redox 
cycling activity itself. Catalase, which converts H2O2 to ½ O2 + H2O, reduces the rate of 
O2 consumption by approximately 50% confirming that H2O2 is the ultimate product of 
redox cycling. 
Superoxide is Produced by Cells Treated with Redox Cyclers 
Apart from the ability to redox cycle, we have shown that HOCD is toxic to PC12 
cells at micromolar concentrations. If these two attributes are related to each other, then 
we would expect to see generation of reactive oxygen species in cells following HOCD 
treatment. Although hydrogen peroxide is the final product of redox cycling, O2 is typically 
reduced first to superoxide before disproportionating to H2O2. We used MitoSOX Red 
fluorescence assay to monitor superoxide production in PC12 cells. A visible increase in 
fluorescence was seen within ten minutes of adding HOCD to the cells (Fig. 10). This 
effect was mimicked by other known redox cyclers, 3-methyl-5-anilino-o-quinone (3MAQ) 
and 9,10-phenanthrenequinone. Cysteinyl-dopamine also causes this fluorescence 
increase but only after about 30 minutes of exposure consistent with its time-dependent 
conversion to HOCD. Neither dopamine nor NaOCl when added separately caused this 
effect, nor did it occur if the dopamine product was made without either dopamine or 
hypochlorite. 
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Figure 10. Superoxide generation by redox cyclers in PC12 cells – PC12 cells were 
grown in a 35-mm diameter imaging chamber and treated with MitoSOX Red. A bright-
field image (A) was obtained followed by fluorescence images (B) before (inset) and after 
addition of the indicated redox cycler (125 μM HOCD, 10 μM 3MAQ, or 10 μM 9,10-
phenanthrenequinone). Magnification bars = 40 μm. 
 
Hypochlorite is Unique in its Ability to Convert Cysteinyl-dopamine into a Redox 
Cycler 
Hypochlorite is a strong oxidizing agent, and it is possible that its effect on 
cysteinyl-dopamine is a consequence of simple oxidation. However, we can discard that 
possibility based on the failure of other common oxidants to mimic its effect, thus making 
hypochlorite unique in this respect (Fig. 11A). Hypochlorite at a concentration of 100 μM 
initiates a very rapid rate of redox cycling. Comparatively, ferricyanide produces a small 
amount of redox cycling activity, whereas ferric ion, perchlorate and methyl viologen 
(paraquat) are all ineffective. Hydrogen peroxide by itself has a negligible effect, even at  
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Figure 11. Sodium hypochlorite is uniquely effective at converting cysteinyl-
dopamine into redox cycling products and is blocked by taurine – (A) Initial rates of 
O2 consumption, recorded as in Fig. 9, were measured in the presence (green) or 
absence (red) of 25 μM dopamine along with cysteine and tyrosinase. Oxidants tested 
were sodium hypochlorite (100 μM), ferric chloride (200 μM), hydrogen peroxide (1.25 
mM), potassium ferricyanide (200 μM), paraquat (200 μM) and potassium perchlorate 
(200 μM). Bars show the average ± standard deviation of three replicate samples. (B) 
Redox cycling was monitored as in Fig. 9A, but the indicated concentration of taurine was 
added before adding NaOCl. The dashed line shows a sample in which 25 mM taurine 
was added after NaOCl and just prior to ascorbic acid. 
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a very high concentration (>1 mM). Since taurine protects against the conversion of 
cysteinyl-dopamine to the toxic product HOCD in PC12 cells, we expected its effect on 
redox cycling to follow suit in the oxygen consumption assay. Indeed, the redox cycling 
activity was inhibited when taurine preceded hypochlorite addition (Fig. 11B). Addition of 
taurine after hypochlorite showed very little change in the redox cycling activity which not 
only indicates that it does not interfere with the redox cycling assay but also reaffirms that 
taurine has no effect on HOCD.  
Myeloperoxidase Can Produce the Hypochlorite Required to Convert Dopamine 
into a Redox Cycler 
Myeloperoxidase catalyzes the reaction of Cl- and H2O2 to produce hypochlorite 
and water. Therefore, substituting hypochlorite with myeloperoxidase and its substrate 
hydrogen peroxide should replicate its effect of converting cysteinyl-dopamine into a 
redox cycler. Indeed, when hydrogen peroxide was provided as substrate for 
myeloperoxidase, ascorbate-dependent redox cycling occurred with a rate proportional 
to H2O2 concentration (Fig. 12). Furthermore, dopamine, hydrogen peroxide, 
myeloperoxidase and Cl- are indispensable for producing the redox cycling product (Fig. 
12B). Myeloperoxidase has both peroxidase and chlorination activities, but hypochlorite 
is produced by the chlorination reaction. Therefore, to check if myeloperoxidase is present 
in PC12 cells to convert cysteinyl-dopamine into HOCD, we tested myeloperoxidase both 
by Western blotting and by chlorination activity. Using both measures, a low basal level 
of myeloperoxidase is found in PC12 cells, and this increases proportionately when cells 
are exposed to varying concentrations of cysteinyl-dopamine or HOCD (Fig. 13). 
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Figure 12. Conversion of dopamine into redox cycling products by 
myeloperoxidase and H2O2 – (A) Samples received dopamine (25 μM), cysteine (37.5 
μM) and tyrosinase (100 units) followed by the indicated concentration of hydrogen 
peroxide and 6.7 μg of myeloperoxidase in 0.1 M KCl. Redox cycling was initiated by 
adding 2.5 mM ascorbic acid. (B) Rate of redox cycling by products of 
myeloperoxidase/H2O2 treatment. Rates were determined as the initial slope following 
ascorbic acid addition from recordings obtained as in (A). Samples lacking 
myeloperoxidase (MPO), dopamine and KCl were obtained with 120 μM H2O2. Bars show 
the average ± standard deviation of three replicate samples. 
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Figure 13. Cysteinyl-dopamine and HOCD increase myeloperoxidase expression 
and activity – PC12 cells were treated with cysteinyl-dopamine or HOCD at the indicated 
concentrations for 24 h. Extracts were tested for myeloperoxidase expression by Western 
blotting (A and D) and assayed for chlorination activity (C and F). Quantification of 
Western blots are shown in B and E. Bars show the average ( ± standard deviation) of 
three replicate samples. 
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It has also been reported that rotenone leads to increased expression of 
myeloperoxidase in neurons and glial cells (129-131). With low concentrations of 
cysteinyl-dopamine or HOCD, 10 nM rotenone causes a marked increase in the level of 
myeloperoxidase (Fig. 14). Concomitantly, rotenone significantly reduces survival of 
PC12 cells treated with cysteinyl-dopamine. On the other hand, addition of rotenone has 
no effect on the greater initial toxicity of HOCD. This differential effect of rotenone 
suggests that it is enhancing the conversion of cysteinyl-dopamine to HOCD. Therefore, 
the dopaminergic toxicity of rotenone is likely due, at least in part, to its effect on 
myeloperoxidase expression. 
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Figure 14. Rotenone increases myeloperoxidase and enhances toxicity of 
cysteinyl-dopamine but not of HOCD – Myeloperoxidase was assayed both by Western 
blotting (A and D) and by chlorination activity (C and F) after 24 h of treatment with 50 μM 
cysDA or 50 μM HOCD in the presence or absence of 10 nM rotenone. Quantification of 
Western blots are shown in B and E. Toxicity was also measured after 24 h of these 
treatments (G and H). Bars show the average (± standard deviation) of 3 
(myeloperoxidase expression), 4 (myeloperoxidase activity), or 9 (toxicity) replicate 
samples. 
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DISCUSSION 
Although the role of dopamine in Parkinson’s disease has been questioned (132), 
there is good evidence that dopamine oxidation contributes to neurotoxicity (15,133-136). 
Studies have suggested that dopamine oxidation metabolites damage mitochondria and 
contribute in a major way to the death of dopamine neurons. For example, dopamine 
oxidation by tyrosinase enhances the toxicity of α-synuclein, particularly the mutant form 
associated with Parkinson’s disease (15,135), and tyrosinase-treated dopamine also 
triggers the mitochondrial permeability transition in isolated brain mitochondria (14). On 
the contrary, increased dopamine and increased L-DOPA, instead of promoting oxidation 
of dopamine, do not seem to accelerate the progression of Parkinson’s disease (132). 
Some of this uncertainty may arise because dopamine oxidation yields different products, 
so it is important to understand which are destructive and the physiological conditions 
under which their formation is favored.  
Considering non-enzymatic oxidation, in the absence of thiol groups, the oxidation 
of dopamine to dopamine-o-quinone may be followed by the insertion of the side chain 
amine in to the o-quinone to form the bicyclic product aminochrome and its metabolite 
5,6-dihydroxyindole (54,137,138). These dopamine oxidation products are also major 
components of neuromelanin, the pigment giving the substantia nigra its dark color. Some 
attention has been focused on the toxicity of these products (139-141), but they are highly 
unstable under physiological conditions. The cyclization of the dopamine quinone is not 
likely to compete with cysteine because it is a slow process (137). Thus dopamine 
oxidation is likely to form a thiol adduct, either with cysteine or glutathione.  Competition 
between glutathione and cysteine for reaction with the dopamine quinone is likely to be 
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more significant, and it is noteworthy in this connection that Parkinson’s patients typically 
have a low concentration of glutathione in the substantia nigra. Also the 
dopamine/glutathione adduct may also be metabolized to cysteinyl-dopamine, making it 
the predominant product.  
Treatment of cells with cysteinyl-dopamine can result in oxidative damage, a rise 
in intracellular calcium, and ultimately apoptosis (82,125,126). Recently, Vauzour et al. 
(127) attributed its toxicity to combined effects of cysteinyl-dopamine itself and DHBT-1 
(7-(2-aminoethyl)-3,4-dihydro-5-hydroxy-2H-1,4-benzothiazine-3-carboxylic acid). 
Dryhurst and colleagues (80,142,143) have shown that DHBT-1 is the principal product 
formed by the air oxidation of cysteinyl-dopamine. It inhibits mitochondrial Complex I, but 
it is a weak cytotoxic agent requiring millimolar concentrations to be effective. A major 
source of ambiguity here is that a specific mode of action has not been determined for 
any of these compounds. 
Our results show that cysteinyl-dopamine is toxic to PC12 cells only once it is 
oxidized by hypochlorite; cysteinyl-dopamine by itself may not cause much damage (Fig. 
8). The product formed by hypochlorite treatment has strong redox cycling activity and 
ability to thereby generate reactive oxygen species. A potent redox cycler may also be 
obtained by treating the 4-methylcatechol/cysteamine product, which lacks the amine of 
dopamine and the carboxyl of cysteine, with hypochlorite. This suggests that the catechol 
ring of dopamine and the amine and thiol of cysteine are required to form the redox cycling 
product. We have also found that 5-amino-o-quinones, like 3-methyl-5-anilino-o-quinone 
and aminochrome, are active redox cycling compounds. We suggest, therefore, that 
hypochlorite converts cysteinyl-dopamine into a compound incorporating this structure by 
55 
 
facilitating attack of the cysteinyl amine on C6 of dopamine. This internal rearrangement 
of cysteinyl-dopamine would make HOCD a 7,8-dihydroxy-1,4-benzothiazine. Indeed, 
NMR and mass spectra of the 4-methylcatechol/cysteamine product support this 
structure. 
The concentrations of dopamine, cysteine and hypochlorite needed to generate an 
active redox cycler are physiologically reasonable (Fig. 9). Although concentrations used 
in our toxicity studies have been relatively on the higher side (Fig. 8), there are a number 
of reasons that need to be considered in this regard. First, formation and toxicity of HOCD 
may be reduced in the presence of protective compounds such as glutathione and 
taurine, both of which have been reported to be low in Parkinson’s patients (144,145). 
Second, the permeability of cysteinyl-dopamine and HOCD may limit their toxicities. It is 
possible that intracellular generation of these compounds may increase effective toxicity 
compared to exogenous addition. Third, HOCD concentrations specified in this work 
assume a 100% yield. Since the yield is undoubtedly less than this, toxicity may occur at 
correspondingly lower concentrations. Finally, Parkinson’s disease is a progressive 
movement disorder which develops over decades, so slow accumulation of damage 
caused by low concentrations of these compounds may be sufficient. 
Like other neurodegenerative disorders, Parkinson’s disease progresses slowly 
and symptoms are usually prominent only at later stages of life. Therefore, it is very 
difficult to analyze the subtle physiological changes occurring at molecular and cellular 
levels over the course of disease progression. To understand the etiology of Parkinson’s 
disease several models depicting the cellular changes underlying the disease have been 
developed, but how well the model mimics the pathophysiology of PD has been the 
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persisting question. Amongst the different models for Parkinson’s disease, the rotenone 
model is very intriguing (45). Rotenone is a non-selective inhibitor of Complex I of the 
mitochondrial electron transport chain and has been found to mimic mitochondrial 
dysfunction in PD. Mitochondrial dysfunction is known to play a role in many 
neurodegenerative diseases, yet remarkably rotenone only models Parkinson’s disease. 
However, the question how rotenone specifically leads to the death of dopamine neurons, 
still remains to be answered.  
Interestingly, recent studies have shown that very low concentrations of rotenone 
lead to increased myeloperoxidase expression. These reports hint that rotenone 
upregulates myeloperoxidase in microglia, and this contributes to the vulnerability of 
dopamine neurons (129,130). Also, myeloperoxidase is significantly higher in postmortem 
tissue from the ventral midbrain of PD patients (131). These observations suggest a 
possible role for myeloperoxidase (MPO) and its product hypochlorite in the rotenone 
model as well as in Parkinson’s disease. Our results with PC12 cells indicate that 
neuronal myeloperoxidase may produce enough hypochlorite to convert cysteinyl-
dopamine to HOCD, but it is also possible that microglial MPO plays a significant or even 
dominant role in vivo. How rotenone increases myeloperoxidase expression is still not 
clear. It is possible that this effect on myeloperoxidase is a downstream effect of the 
inhibition of complex I. Or rotenone could have an unrecognized second mode of action 
independent of mitochondrial complex I inhibition. 
The effects of hypochlorite presented here integrate many observations and 
provide a new perspective for Parkinson’s disease (Fig. 7). Myeloperoxidase produces 
hypochlorite which oxidizes the dopamine oxidation product cysteinyl-dopamine to yield 
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HOCD. Redox cycling of HOCD produces superoxide and hydrogen peroxide creating 
oxidative stress. Cysteinyl-dopamine and HOCD also increase expression of 
myeloperoxidase, which (together with hydrogen peroxide generated by redox cycling) 
promotes continuous conversion of cysteinyl-dopamine to HOCD. The expected 
consequence would result in increased oxidative stress eventually leading to death of 
dopamine neurons.  
Parkinson’s disease affects only a small part of the population, so it is safe to 
assume that there are certain inherent mechanisms that protect against or repair the 
damage caused by oxidative stress in dopaminergic neurons. Therefore, for Parkinson’s 
disease to develop, it is imperative to figure out which destructive events occur and which 
protective mechanisms fail. Another long standing issue to be probed is how dopamine 
oxidized compounds interact with genetic and environmental factors to contribute to the 
progression of the disease. The observation that hypochlorite converts cysteinyl-
dopamine into a toxic redox-cycling product is not only an unappreciated link connecting 
dopamine oxidation, oxidative stress and the rotenone model of Parkinson’s disease but 
may also offer a promising new approach from a therapeutic standpoint.  
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CHAPTER 5 – HOCD ACTIVATES THE INTRINSIC APOPTOSIS PATHWAY 
INTRODUCTION 
In the year 1972, the term apoptosis was described in a classic paper by Kerr, 
Wyllie and Currie (146). Apoptosis then was recognized as a morphologically distinct form 
of cell death; however, conceptual evidence of the phenomenon had been previously 
known (146-148). Our understanding of the detailed mechanisms involved in apoptosis 
stem from an elaborate study of 'programmed cell death' during the development of the 
nematode Caenorhabditis elegans (149). In this investigation, it was shown that an adult 
worm comes in to being from the generation of 1090 somatic cells, of which 131 cells 
invariably undergo 'apoptosis.' These 131 cells, irrespective of the physiological 
conditions, are programmed to die during the developmental process. This is consistent 
between worms thereby indicating remarkable control in this system. Since then, 
apoptosis has been widely recognized as a characteristic mode of "programmed cell 
death," which involves genetically controlled depletion of cells. Apart from its mechanistic 
approach of maintaining homeostasis, it is also involved during immune reactions or cell 
damage (150). 
There are certain biochemical and/or morphological features that not only 
characterize apoptotic events but also help distinguish them from other modes of cell 
death. Major histological features that define apoptosis are cell shrinkage and chromatin 
condensation (146). Chromatin condensation is a typical feature of apoptosis during 
which the electron dense nuclear material aggregates around the nuclear membrane and 
may further result in pyknosis. DNA fragmentation is also well-known, where DNA is 
cleaved into small fragments. This typical feature is often referred to as “DNA laddering.” 
59 
 
(151). Another morphological marker that usually occurs is membrane blebbing. It 
involves formation of apoptotic cells due to pinching off of the cell membrane. Although 
the cytoplasmic contents are dense, interestingly, the integrity of organelles and 
membrane is intact.  
Unlike apoptosis, necrosis is an energy-independent degradative process where 
cells undergo passive death. Necrosis affects larger populations of cells unlike apoptosis 
wherein usually individual or clusters of cells are affected in a controlled manner. 
Alternative terms such as "oncotic cell death" and "oncotic necrosis" have been proposed 
to describe cell death by necrosis (152,153).  
Necrosis requires ATP and involves direct damage to the cell membranes. Some 
of the major features that typically characterize necrosis are cell swelling; formation of 
vacuoles and loss of plasma membrane (146,153,154). Since there is complete loss of 
cell membrane in necrosis, an inflammatory reaction is usually elicited due to the release 
of cytosolic components into the surrounding tissue. Unlike necrosis, inflammatory 
reactions are neither associated with the apoptotic process nor with the removal 
mechanism. This is primarily due to the fact that the plasma membrane of apoptotic cell 
bodies remains intact thereby preventing any release of the cellular constituents into the 
surrounding tissues (155,156). 
Apoptosis is primarily divided into two main pathways – the extrinsic or death 
receptor pathway and the intrinsic or mitochondrial pathway.  
The death receptor pathway involves transmembrane receptor-mediated 
signaling. It involves activation of death receptors belonging to the tumor necrosis factor 
receptor gene superfamily such as Fas, TNFαR, DR3, DR4 and DR5 (157-162). These 
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receptors have a similar cytoplasmic “death domain.” Some of these death domains are 
named after their corresponding receptor, namely, Fas-associated death domain (FADD) 
or TNF-α receptor associated death domain (TRADD) (157). The death signal is 
characteristically initiated when homologous trimeric death receptor ligands bind to their 
corresponding death receptors leading to their oligomerization. Among the most well 
studied ligand-receptor complexes are FasL/FasR and TNF-α/TNFR1 (157-162). 
The intrinsic apoptotic pathways, on the contrary, are non-receptor mediated 
signaling pathways that produce intracellular signal targeting molecules within the cell. 
They are mitochondrially initiated events (163). The trigger could initiate a signal that may 
regulate the pathway negatively or positively. Irrespective of the type of stimulus, 
mitochondrial membrane changes accompany the intrinsic pathway of apoptosis. 
Perturbations in the mitochondrial inner membrane not only result in an opening of the 
mitochondrial permeability transition (MPT) pore but also loss of membrane potential 
eventually releasing the mitochondrial content into the cytosol (163).  
In the intrinsic pathway, the mitochondrial events are regulated by the Bcl-2 family 
of proteins (164). Moreover, p53, the tumor suppressor protein, also has an integral part 
to play as it regulates multiple proteins of the Bcl-2 family (165). However, the mechanistic 
details of this controlled regulation are not well elucidated. The Bcl-2 family involves both 
pro-apoptotic as well as anti-apoptotic proteins. Both are involved with mitochondrial 
membrane integrity and control the release of cytochrome c from the mitochondria by 
regulating the outer mitochondrial membrane permeability. Among these, anti-apoptotic 
proteins include Bcl-2, Bcl-x, Bcl-XL, Bcl-XS, Bcl-w and BAG, whereas pro-apoptotic 
proteins include Bcl-10, Bax, Bak, Bid, Bad, Bim, Bik, and Blk. Pro-apoptotic proteins are 
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mostly BH123 proteins, having three Bcl-2 homology domains. However, some pro-
apoptotic proteins such as PUMA, NOXA, etc., are BH3 proteins only. And anti-apoptotic 
proteins mostly have all four Bcl-2 homology domains. Under normal conditions, pro-
apoptotic proteins are in an inactive state where they are either sequestered in the cytosol 
with an anti-apoptotic protein or conjugated to some other proteins inhibiting their effect. 
Usually reciprocal regulation exists between these two classes of the Bcl-2 family of 
proteins (164). 
During apoptosis, the external stimulus such as any radiation or toxin, may cause 
either a double-stranded or single-stranded break in DNA. For example, in the case of a 
double-stranded break, the damage is sensed by two classes of proteins such as ATM 
(Ataxia Telangiectasia Mutated) and ATR (Ataxia Telangiectasia and Rad3 related 
protein) (166,167). Both proteins are serine/threonine kinases. These proteins could 
further phosphorylate other serine/threonine kinases, checkpoint kinase 1 (Chk1) and 
checkpoint kinase 2 (Chk2), eventually activating them (166,167). Once activated, these 
kinases tend to activate tumor suppressor protein p53. p53 protein under normal 
conditions is in an inactive state. Mdm2 is usually conjugated to p53 and marks p53 for 
ubiquitination. In apoptosis, once Chk1 and/or Chk2 are activated, phosphorylation of p53 
prevents its conjugation to Mdm2 and therefore, p53 survives subsequent ubiquitination 
and proteasome degradation, and instead phosphorylated p53 forms a tetramer and 
initiates transcription. p53 leads to expression of many proteins such as proteins involved 
in DNA repair, another tumor suppressor protein p21 that arrests the cell cycle 
progression, and also some pro-apoptotic proteins such as Puma and Noxa (168,169).  
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The pro-apoptotic proteins such as Puma and Noxa, belonging to the Bcl-2 family, 
are found to play an important role in p53-mediated apoptosis (168). Once expressed, 
they tend to sequester the anti-apoptotic proteins in the cytoplasm, thereby increasing the 
expression of other pro-apoptotic proteins. Studies have reported an increase in the levels 
of BAX due to overexpression of Puma (168). This resulted in a conformational change 
in BAX and its translocation to outer mitochondrial membrane. Another study has shown 
that expression of Noxa leads to its localization to the mitochondrial membrane, resulting 
in inactivation of anti-apoptotic proteins (169). This will lead to the formation of the 
apoptosis-induced channel in the outer mitochondrial membrane and release of 
cytochrome c in to the cytoplasm. Once in the cytoplasm, cytochrome c encounters 
cytoplasmic protein Apaf-1 (Apoptotic Protease Activation factor-1) (170,171). Apaf-1 has 
a CARD domain (caspase recruitment domain). When cytochrome c binds to this Apaf-1 
protein, it aggregates to form an apoptosome (170,171). Formation of the apoptosome 
recruits pro-caspases having a similar CARD domain, for example, pro-caspase-9, and 
auto-activates them. Once activated, these caspases further activate other executioner 
caspases such as caspases 3, 6 or 7. Proteins such as Smac/DIABLO and HtrA2/Omi 
also participate by inhibiting IAP (inhibitors of apoptosis proteins) activity (172-175). 
The execution phase is the last step in the apoptosis process. Activation of 
caspases mark the beginning of this phase. Caspases are a group of cysteine-dependent 
aspartate-directed proteases. As the name suggests, caspases are proteolytic enzymes 
that cleave proteins at aspartic acid residues. The substrate specificities of caspases may 
differ among the group of caspases. Caspases usually exist in inactive forms called 
procaspases. All procaspases have a pro-domain, a large subunit and a small subunit. 
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Once activated by a signaling cascade, they are cleaved to their active intermediate form. 
Apart from their ability to activate other procaspases they can also aggregate and 
autoactivate themselves. This activation of caspases creates a protease cascade thereby 
amplifying the apoptotic signal, and eventually leading to cell death. Among the ones that 
are identified, caspases are broadly classified into two categories, initiator caspases 
(caspases 2, 8, 9, 10) and effector or executioner caspases (caspases 3, 6, 7). 
Additionally, a class of inflammatory caspases (caspase – 1, 4, 5) (176,177) and several 
other caspases (11, 12, 13, 14) (178-181) are also known. Of all the caspases, caspase-
3 is especially significant. It can be activated by three important initiator caspases: 8, 9 
and 10. Caspases-3, 6 and 7 are the effector caspases that cause the morphological and 
biochemical changes in the cell such as activation of cytoplasmic endonucleases that 
degrade nuclear material, activation of proteases that degrade nuclear as well as 
cytoskeletal proteins and cleavage of substrates like poly-ADP ribose polymerase 
(PARP), cytokeratins, the plasma membrane cytoskeletal protein alpha fodrin, etc. (182). 
Our study has already shown that HOCD is toxic to PC12 cells at micromolar 
concentrations. However, the mechanism of cell death is not known. Therefore, the focus 
of this investigation was to elucidate the underlying mechanism of cell death when PC12 
cells are treated with HOCD. This is important both to determine the mechanism of HOCD 
toxicity and to see how this correlates with the mechanism of dopaminergic neuron death 
in Parkinson’s disease and its various chemically-induced models. 
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RESULTS 
We have shown that HOCD and other redox cyclers lead to superoxide generation 
and death of PC12 cells. To elucidate the mechanism of cell death, it is important to 
investigate certain morphological and biochemical markers that would help differentiate 
between different modes of cell death. Among the morphological markers, membrane 
blebbing was an early candidate. During microscopic examination of PC12 cells after 
HOCD treatment, a remarkable change in the morphology of the cells was observed. 
Membrane blebs were found on the surface of a few of the cells in addition to small 
individual apoptotic bodies in the medium (Fig. 15). This phenomenon of membrane 
blebbing is a characteristic feature of apoptotic cell death.  
 
Figure 15. Formation of membrane and apoptotic blebs – Bright field microscopic 
images of PC12 cells taken after 24 h of treatment with 200 µM HOCD, shows the 
formation of membrane and/or apoptotic blebs (indicated by arrows). 
 
To confirm that cells are undergoing death via apoptosis, we checked for the 
presence of cleaved poly-ADP ribose polymerase, an apoptotic marker that usually 
appears late in the pathway when executioner caspases are activated. By western 
blotting, we found increased levels of cleaved-PARP protein when PC12 cells were 
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treated with HOCD thereby confirming apoptosis as the selected mode of cell death (Fig. 
16).  
Following the observation of cleaved PARP protein, we wanted to investigate the 
possible involvement of mitochondria in this apoptotic process. Caspase-9 is an initiator 
caspase that is activated primarily after cytochrome c is released from the mitochondria. 
Therefore, we checked for the level of active caspase-9. We observed an increase in the 
amount of active caspase-9 (Fig. 17), confirming our hypothesis that the mode of cell 
death in PC12 cells treated with HOCD was mitochondrially driven. 
Since p53 has been reported to play an important role in the mitochondrially 
mediated apoptotic pathway, we checked for the level of p53 in whole cell lysates of PC12 
cells treated with HOCD by western blotting. Indeed, we found increased p53, further 
indicating involvement of mitochondria in this apoptotic process (Fig.18).  
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Figure 16. Increased level of cleaved poly-ADP ribose polymerase – Western blot 
analysis of HOCD-treated PC12 cell lysates was performed. HOCD concentration was 
200 µM, and cell lysates were prepared after 72 h of HOCD treatment. Whole cell lysates 
were resolved using SDS PAGE and probed with anti-PARP antibody. (A) Protein levels 
obtained by blot analysis (A) were also quantified (B) and normalized to the loading 
control, GAPDH. 
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Figure 17. Increased level of active caspase-9 – Western blot analysis of HOCD-
treated PC12 cell lysates was performed. HOCD concentration was 200 µM, and cell 
lysates were prepared after 72 h of HOCD treatment. Whole cell lysates were resolved 
using SDS PAGE and probed with anti-active caspase-9 antibody. (A) Protein levels 
obtained by blot analysis (A) were also quantified (B) and normalized to the loading 
control, GAPDH. 
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Figure 18. Level of p53, a regulator of mitochondrially-mediated apoptosis –  
Western blot analysis of HOCD-treated PC12 cell lysates was performed. HOCD 
concentration was 200 µM, and cell lysates were prepared after 72 h of HOCD treatment. 
Whole cell lysates were resolved using SDS PAGE and probed with anti-p53 antibody. 
(A) Protein levels obtained by blot analysis (A) were also quantified (B) and normalized 
to the loading control, GAPDH. 
 
 
0
1
2
3
4
5
Control 200 µM HOCD
p
5
3
 (
re
la
ti
v
e
 u
n
it
s
)
**
B)
69 
 
DISCUSSION 
In Parkinson’s disease models, activation of the mitochondria-dependent apoptotic 
pathway has been found to be prevalent in the death of dopaminergic neurons (183,184). 
For instance, mitochondrial release of cytochrome c, followed by caspase-9 activation 
and eventual apoptotic nigral cell death was observed for the MPTP model in mice (185). 
These events were found to be regulated by the pro-apoptotic protein Bax (185-187). 
Supporting this finding, another study showed that dopamine neurodegeneration was 
attenuated by overexpressing the anti-apoptotic protein Bcl-2 (188,189) or by targeting 
caspase-9 or Apaf-1 (190,191).   
Furthermore, many familial forms of Parkinson’s disease have shown either direct 
or indirect correlation between gene mutations and the mitochondrial apoptotic pathway 
(192). Overexpression or aggregation of α-synuclein have been shown to induce 
caspase-9 and caspase-3 activation damaging dopaminergic neurons (193). Similarly, 
mutation in LRRK2 (194), PINK1 (195,196) and PARKIN (197) all lead to cytochrome c 
release.  
Apoptosis has also been widely studied in mammalian cell lines and primary 
neuronal cultures, in regards to dopaminergic neurons and Parkinson’s disease. 
Tabakman et al. showed increased activities of JNK and p38 in PC12 cells due to 
neurotrophic factor deprivation (198). Mitochondrial cytochrome c release and increased 
levels of activated caspase-9 were observed in PC12 cells (199). Also, in mesencephalic 
and MN9D primary dopaminergic neurons, cytochrome c release from mitochondria and 
activation of caspases were observed after 6-OHDA and MPP+ treatment (200). Similar 
events were recorded in MPP+ treated (201) and 6-OHDA treated SH-SY5Y cells (202). 
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Even in the rotenone model for PD, caspase activation was observed in human 
neuroblastoma cells (203), in addition to cleavage of PARP, DNA fragmentation and cell 
death (204). 
Dopamine quinone can lead to opening of the mitochondrial transition pore due to 
the impairment of oxidative phosphorylation and mitochondrial swelling. This may further 
lead to the release of both pro-apoptotic and anti-apoptotic factors (14) as well as non-
specific release of cytochrome c initiating apoptotic events (205). Due to the slow rate of 
neuronal death in PD, detection and assessment of mode of cell death is very difficult. 
Using various mechanisms, apoptotic dopaminergic neurons have been reported in 
substantia nigra of PD patients (206-210), where increased expression of CD95/Fas and 
p53 have also been detected (211). 
Involvement of the extrinsic pathway in the death of dopaminergic neurons, though 
not predominant, has been well investigated. Expression of FasL and Fas receptor is 
found in neurons, astrocytes and glial cells, however, astrocytes have interestingly shown 
resistance to Fas-mediated apoptosis (212). Significantly higher levels of soluble Fas 
were first reported by Mogi et al. in nigrostriatal dopaminergic regions of PD patients 
(213). Hayley et al. also reported the possible connection of c-Jun-Fas signaling to the 
loss of dopaminergic function in the MPTP-induced PD model (214). Apart from Fas 
signaling, altered levels of TNF-α were detected in glial cells in substantia nigra, in 
cerebrospinal fluid (CSF) and brain of PD patients and also in lymphocytes in PD patients. 
Compared to the death receptor pathway, involvement of the mitochondrial mediated 
apoptotic pathway in death of dopaminergic neurons has been well documented. 
Although both extrinsic and intrinsic pathways of apoptosis seem to be involved in 
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Parkinson’s disease, the intrinsic pathway is more prevalent, probably due to the energy 
deprivation. 
Neurons undergo apoptosis because of the informative signal received from either 
external stimuli or internal stimuli. Intracellular signaling depends on cell type, state of 
differentiation and maturity as well as developmental history, whereas extracellular 
factors that affect cell fate are appearance and disappearance of hormones, growth 
factors, cytokines and cell matrix interactions. Multiple factors are involved in the 
execution of apoptotic cell death in PD and once these factors are activated, they all lead 
to ATP depletion. 
However, recent studies have shown evidence of possible interplay between the 
two pathways, where the components involved in one pathway could influence the other. 
One of the examples of such cross-talk is a study showing that initiation of the apoptotic 
pathway via Fas receptor activation has led to mitochondrial damage via interaction 
between caspase-8 and the pro-apoptotic protein Bid. Also, since recent findings have 
shown that apoptosis is a reversible process, inhibition of caspase activity could be an 
important strategy from a cell survival point of view. In fact studies have shown that 6-
OHDA-induced death of dopaminergic neurons was prevented in the presence of 
caspase inhibitor (215,216). 
Our results however, do not disregard the possibility of an interplay between the 
extrinsic and intrinsic pathways. It is possible that caspase-8 activation could trigger 
mitochondrial membrane change and subsequent caspase-9 activation. However, use of 
mammalian cell lines does introduce some limitations. Mammalian cell lines may not offer 
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the physiological conditions to study the extrinsic pathway and therefore further restrict 
observation of its influence on or reaction to activation of the intrinsic pathway. 
 Another question is how the genetic factors linked to Parkinson’s disease are 
connected to the induction of apoptosis. For some, a direct relationship is plausible. 
Parkin and PINK1 are involved in mitophagy, the process by which defective mitochondria 
are removed from the cells. Mitochondria that fail to maintain a membrane potential 
across the inner membrane are culled by mitophagy in a process mediated by Parkin and 
PINK1 (217). Therefore, it seems reasonable that a mutation in either protein would 
interfere with the removal of dysfunctional mitochondria and would contribute to the 
release of cytochrome c in to the cytoplasm and triggering of the intrinsic pathway of 
apoptosis. 
 The involvement of α-synuclein in apoptosis is more elusive. DiMaio et al. have 
reported that α-synuclein binds to TOM20, a mitochondrial import protein and inhibits 
protein import into mitochondria (218). Impairment of this system would likely lead to 
mitochondrial degradation and could contribute to initiation of the intrinsic pathway of 
apoptosis. At the same time, Parkinson’s disease is characterized by α-synuclein 
aggregates found in Lewy bodies. How oxidative stress and mitochondrial dusfunction 
contribute to α-synuclein proteinopathy is not clear. It has been suggested that clearance 
of protein aggregates occur by autophagy or proteasomal action and that these processes 
compete with mitophagy for cellular components such as Bcl-2 or ubiquitin. Thus, the 
occurrence of α-synuclein aggregates could interfere with the clearance of defective 
mitochondria and predispose the cell to death by the mitochondrial pathway of apoptosis.  
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 The picture emerging, therefore, is that HOCD causes oxidative stress which leads 
to mitochondrial damage and activation of the intrinsic pathway of apoptosis. Clearly, 
however, we are just beginning to connect the dots and understand the roles and 
relationship of all of the factors contributing to the death of dopamine neurons in 
Parkinson’s disease. 
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CHAPTER 6 – FUTURE DIRECTIONS 
Our study has shown that cysteinyl-dopamine by itself is not toxic. Rather it is the 
oxidized product of cysteinyl-dopamine that is toxic. We showed that hypochlorite 
produced by myeloperoxidase oxidizes cysteinyl-dopamine into a cytotoxic redox cycling 
compound, called hypochlorite-oxidized cysteinyl-dopamine (HOCD), capable of 
generating free radicals and thereby creating oxidative stress.  Also, HOCD was found to 
be toxic to catecholaminergic PC12 cells at micromolar concentrations. However, since 
the cytotoxic effect of HOCD was tested in mammalian cell lines, it will be interesting to 
check its effect in primary cultured neurons and animal models.  
If HOCD is found to be toxic to primary cultured neurons and/or in animal models, 
it will be interesting to see if HOCD treatment leads to the aggregation and accumulation 
of α-synuclein and ultimately formation of Lewy bodies. Similarly, following the 
observation of Lewy body formation, it will be important to see the effect of HOCD 
treatment on dopaminergic neurons. There have been several animal models developed 
over the years to study the etiology of Parkinson’s disease, including pathologies caused 
by rotenone, 6-OHDA, MPTP and LPS. In addition to the α-synuclein pathology and death 
of dopaminergic neurons, if HOCD recapitulates the delayed, progressive symptoms of 
Parkinson’s disease then it could be an alternative PD model. Moreover, if HOCD is the 
natural trigger for PD, then it will be an important tool for elucidating the events involved 
in the onset and progression of the disease.   
Since microglial inflammation is known to play a significant role in the pathogenesis 
of Parkinson’s disease, it is important to see what effect HOCD would have on the 
activation of microglia. Microglial activation is usually measured by an increase in NADPH 
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oxidase (NOX-2) activity. If HOCD leads to overexpression of NOX-2, in addition to the 
α-synuclein pathology and death of dopamine neurons, then it would be imperative to 
sketch out the symptomatic events in a chronological order to elucidate the underlying 
molecular mechanism and its timing. Furthermore, our study showed that hypochlorite, 
responsible for converting cysteinyl-dopamine in to a toxic redox cycler, was 
predominantly produced by myeloperoxidase. However, the effect of cysteinyl-dopamine 
in the absence of myeloperoxidase remains to be seen. Therefore, it will be important to 
check the effect of cysteinyl-dopamine and HOCD in primary neurons and/or animal 
models with inhibited myeloperoxidase activity.  
The toxicity of HOCD was attributed to its ability to redox cycle and thereby 
generate free radicals causing oxidative stress. However, as mentioned earlier 
compounds capable of redox cycling in vitro may not necessarily redox cycle in vivo. 
Therefore, a next step would be to observe and measure the redox cycling activity of 
HOCD in vivo. Likewise, we also do not disregard the possibility that HOCD may have an 
additional mode of action besides redox cycling. Thus, it will be necessary to determine 
the protein interactions of HOCD in vivo. However, this may be feasible experimentally 
only once we deduce the structure of HOCD. 
Additionally, our study has shown that taurine was able to protect PC12 cells 
against cysteinyl-dopamine but not HOCD. Taurine is a sulfur-containing amino acid. 
Since it contains a sulfonic acid group instead of a carboxyl group, it is not a typical amino 
acid. Although taurine was considered as a non-essential amino acid, recent studies have 
indicated that taurine is essential for humans. However, humans have limited capacity to 
synthesize taurine themselves, compared to other mammals, due to relatively low activity 
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of the enzyme required for a crucial transformation step in the synthesis of taurine. 
Taurine does have the ability to cross the blood brain barrier. Moreover, taurine is a 
hypochlorite scavenger which enables it to protect cysteinyl-dopamine. Since PD patients 
have low levels of taurine, we suspect taurine to be an important factor in the therapeutic 
field for Parkinson’s disease. It will be interesting to see if supplementing taurine rescues 
the PD symptoms in animal models. 
 It will be important to determine the chemical structure of HOCD and to develop 
methods for detecting it in trace amounts. This will be necessary to confirm that HOCD is 
present in the midbrain of patients with PD. Furthermore, if HOCD or its metabolites can 
be detected in cerebrospinal fluid or blood, it might provide an opportunity for the early 
diagnosis of Parkinson’s disease before motor symptoms appear.  
 The discovery of HOCD, nonetheless, opens multiple new approaches to study the 
etiology of Parkinson’s disease at molecular as well as cellular levels. Hopefully, future 
research exploring these avenues will direct us to advanced therapies for curing 
Parkinson’s disease. 
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Oxidation of dopamine to toxic metabolites is considered to be one of the prime 
factors involved in the death of dopaminergic neurons in Parkinson’s disease. Some 
dopamine oxidation products have the capability to redox cycle in the presence of 
molecular oxygen, further contributing to oxidative stress. Therefore, our aim here was to 
study the redox cycling of dopamine oxidized metabolites and elucidate the underlying 
mechanism by which they cause oxidative stress.   
Redox reactions involve transfer of one or more electrons between two compounds 
resulting in either oxidation or reduction. In redox cycling, a compound undergoes 
alternate oxidation and reduction, transferring electrons from a reductant to molecular 
oxygen. Therefore, we began by investigating different modes of redox cycling by 
measuring the rate of oxygen consumption using a Clark-type oxygen electrode in the 
presence of different reductants. We compared chemically synthesized redox cyclers 
such as menadione, 6-hydroxydopamine (6-OHDA), 3-methyl-5-anilino-1,2-
benzoquinone (3-MAQ) and 9,10-phenanthrenequinone, using ascorbic acid and 
dithiothreitol (DTT) as reductants. Addition of superoxide dismutase diminished DTT-
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dependent redox cycling activity (except in the case of menadione) but had no effect on 
the ascorbate-dependent redox cycling activity. This suggests that DTT drives a two-
electron reduction whereas ascorbate causes a one-electron reduction. NADH-
dependent redox cycling mediated by mitochondria was also studied using 3-MAQ. This 
mitochondrially mediated redox cycling activity was inhibited by mersalyl acid, thereby 
suggesting the involvement of the outer-mitochondrial membrane protein, NADH-
dependent cytochrome b5 reductase, in the redox cycling mechanism. 
We identified hypochlorite-oxidized cysteinyl-dopamine (HOCD) as a redox cycling 
product and a potential candidate for dopaminergic neuron toxicity in the progression of 
Parkinson’s disease. The dopamine oxidation product cysteinyl-dopamine has attracted 
attention as a contributor to the death of dopaminergic neurons in Parkinson’s disease.  
Treatment of cysteinyl-dopamine with hypochlorite yields an even more cytotoxic product.  
This product, HOCD, has potent redox-cycling activity and initiates production of 
superoxide in PC12 cells. Taurine, which scavenges hypochlorite, protects PC12 cells 
from cysteinyl-dopamine but not from HOCD, suggesting that HOCD, not cysteinyl-
dopamine itself, is toxic.  Furthermore, rotenone, which enhances expression of the 
hypochlorite-producing enzyme myeloperoxidase, increases the cytotoxicity of cysteinyl-
dopamine but not of HOCD. This suggests that dopamine oxidation to cysteinyl-dopamine 
followed by hypochlorite-dependent conversion to a cytotoxic redox-cycling product 
HOCD, leads to the generation of reactive oxygen species and oxidative stress and may 
contribute to the death of dopaminergic neurons.  
Our findings of HOCD toxicity in PC12 cells was followed by our study to determine 
the mode of cell death. The morphological changes in the cell such as membrane 
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blebbing and appearance of biochemical markers such as cleaved poly-ADP ribose 
polymerase and active caspase-9 suggested cell death by apoptosis. Moreover, 
increased expression of tumor suppressor protein p53, indicated mitochondrial mediated 
apoptotic cell death. Our observations have raised an unappreciated possibility that may 
link dopamine oxidation, microglial inflammation, oxidative stress and the rotenone model 
of Parkinson’s disease. Furthermore, it offers a promising new approach in the search for 
a therapeutic cure for Parkinson’s disease. 
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